Content area

|
|

Amyloid transthyretinkardiomyopati

Forfatter(e)
Peter Riis Hansen1, 2 & Martin Krakauer3

1) Hjertemedicinsk Afdeling, Herlev-Gentofte Hospital 2) Institut for Klinisk Medicin, det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Afdelingen for Nuklearmedicin, Herlev-Gentofte Hospital

 

Ugeskr Læger 2020;182:V11190627

Reference: 
Ugeskr Læger 2020;182:V11190627

Peter Riis Hansen & Martin Krakauer:

Transthyretin amyloid cardiomyopathy

Ugeskr Læger 2020;182:V11190627

Transthyretin amyloid cardiomyopathy (ATTR-CM) resulting from deposition of transthyretin amyloid fibrils in the heart is an underrecognised cause of heart failure in the elderly and is associated with a poor life expectancy. The diagnosis can now be made by radionuclide imaging with bone tracers, provided absence of plasma-cell dyscrasia. Recent evidence has suggested a considerable prevalence of ATTR-CM, and effective treatment has become available. This review summarises these new developments, which have ushered a new era in the detection and clinical management of ATTR-CM.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Gert Frank Thomsen | 17/02
1 Kommentar
af Kaare Rossel | 17/02
1 Kommentar
af Niels Rokkjær | 16/02
1 Kommentar
af Niels Egund | 15/02
2 kommentarer
af Astrid Hanna M. Schulze | 14/02
1 Kommentar
af Jens Gram-Hansen | 11/02
3 kommentarer
af Poul Erik Rørbæk | 11/02
1 Kommentar